MedTrace Logo

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions

NCT00883883 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-03-29

No results posted yet for this study

Summary

To demonstrate the relative bioequivalence of Cefdinir and Omnicel 250 mg/5 ml fed conditions.

Conditions

  • Healthy

Interventions

DRUG

Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)

DRUG

Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)

Sponsors & Collaborators

Principal Investigators

  • Benoit Girard, M.D. · SFBC Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
56 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2005-05-31
Completion
2005-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883883 on ClinicalTrials.gov